Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53

Cancer Prevention Research

Volumn 1, Issue 6, 2008, Pages 439-451

  Tang, Yaxiong ^a   Simoneau, Anne R ^a,b   Xie, Jun ^b   Shahandeh, Babbak ^b   Zi, Xiaolin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE; CHALCONE DERIVATIVE; DRUG DERIVATIVE; FLAVOKAWAIN A; KAVA; MUTANT PROTEIN;

ANIMAL; ARTICLE; BLADDER TUMOR; CELL CYCLE; CELL STRAIN HCT116; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; NUDE MOUSE; PAPILLARY CARCINOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CELL CYCLE; CELL LINE, TUMOR; CHALCONE; CHALCONES; DRUG RESISTANCE, NEOPLASM; GENES, P53; HCT116 CELLS; HUMANS; KAVA; MICE; MICE, NUDE; MUTANT PROTEINS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61749083799     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0165     Document Type: Article

References (53)

1. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat Res 2002;506-507:21-8.
2. Kamat AM, Lamm DL. Diet and nutrition in urologic cancer. W V Med J 2000;96:449-54.
3. Singh AV, Franke AA, Blackburn GL, Zhou JR. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 2006;66:1851-8.
4. Henderson BE, Kolonel LN, Dworsky R, etal. Cancer incidence in the islands of the Pacific. Natl Cancer Inst Monogr 1985;69:73-81.
5. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999;125: 589-97.
6. Le Marchand L, Hankin JH, Bach F, etal. An ecological study of diet and lung cancer in the South Pacific. Int J Cancer 1995;63:18-23.
7. Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000; 59:420-2.
8. Zi X, Simoneau AR. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvementof Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res 2005;65:3479-86.
9. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin upregulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgenindependent prostate cancer cells. Cancer Res 2000;60:5617-20.
10. Zi X, Guo Y, Simoneau AR, etal. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnta ntagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005;65:9762-70.
11. Sanchez-Carbayo M, Socci ND, Charytonowicz E, etal. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002;62:6973-80.
12. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci U S A 1983;80:2926-30.
13. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994;79: 573-82.
14. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001;98:5043-8.
15. Porter LA, Donoghue DJ, et al. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 2003;5:335-47.
16. Bulavin DV, Higashimoto Y, Demidenko ZN, et al. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 2003;5: 545-51.
17. StClair S, Manfredi JJ. The dual specificity phosphatase Cdc25C is a directt argetfo r transcriptional repression by the tumor suppressor p53. Cell Cycle 2006;5:709-13.
18. Imbriano C, Gurtner A, Cocchiarella FD, et al. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 2005;25:3737-51.
19. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-15.
20. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
21. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001; 21:4129-39.
22. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000;60:5934-6.
23. Walker RE. Renewal of cell populations in the female mouse. Am J Anat1960;102:95-100.
24. Yao R, Lemon WJ, Wang Y, Grubbs CJ, Lubet RA, You M. Altered gene expression profile in mouse bladder cancers induced by hydroxy butyl (butyl) nitrosamine. Neoplasia 2004;6:569-77.
25. Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
26. Doherty SC, McKeown SR, McKelvey-Martin V, etal. Cell cycle checkpointfunct ion in bladder cancer. J Natl Cancer Inst 2003;95:1859-68.
27. Niehans GA, Kratzke RA, Froberg MK, Aeppli DM, Nguyen PL, Geradts J. G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. Br J Cancer 1999;80:1175-84.
28. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119: 1513-8.
29. Spruck CH 3rd, OhneseitPF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54: 784-8.
30. Gonzalgo ML, Hayashida T, Bender CM, etal. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998;58:1245-52.
31. Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 2003;70:601-4.
32. Cordon-Cardo C, Dalbagni G, Saez GT, etal. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994;56: 347-53.
33. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158: 1955-9.
34. Cheng HL, Liu HS, Lin YJ, etal. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005;92:1906-14.
35. Coogan CL, Estrada CR, Kapur S, Bloom KJ. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004;63:786-90.
36. Jebar AH, HurstCD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25.
37. Dinney CP, McConkey DJ, Millikan RE, etal. Focus on bladder cancer. Cancer Cell 2004;6:111-6.
38. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991;6:2305-9.
39. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13.
40. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Dräger BJ. Frequent and heterogenous expression of cyclin-dependentkin ase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 1998;77:515-21.
41. Franke KH, Miklosi M, Goebell P, etal. Cyclin-dependentkinase inhibitor p27KIP1 is expressed preferentially in early stages of urothelial carcinoma. Urology 2000;56:689-95.
42. De Clercq A, Inze D. Cyclin-dependentkinase inhibitors in yeast, animals, and plants: a functional comparison. CritRe v Biochem Mol Biol 2006;41: 293-313.
43. Ahmad N, Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev 1999;57:78-83.
44. Stoner GD, Mukhtar H. Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 1995;22:9-80.
45. Woo HH, Jeong BR, Hawes MC. Flavonoids: from cell cycle regulation to biotechnology. Biotechnol Lett 2005;27:365-74.
46. Nakayama K, Ishida N, Shirane M, etal. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.
47. Dowen SE, Neutze DM, Pett MR, et al. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene 2003;22:2531-40.
48. Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002;161:207-16.
49. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 2003;4:251-6.
50. Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 2001;98:2515-20.
51. Wang Y, Decker SJ, Sebolt-Leopold J, et al. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-13.
52. Wang Y, Li J, Booher RN, etal. Radiosensitization of p53 mutant cells by PD0166285, a novel G (2) checkpointabrogat or. Cancer Res 2001;61: 8211-7.
53. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.